Research on the inhibition for aseptic loosening of artificial joints by Sr-doped calcium polyphosphate (SCPP) in vivo
- 4 October 2021
- journal article
- research article
- Published by IOP Publishing in Biomedical Materials
- Vol. 16 (6), 065017
- https://doi.org/10.1088/1748-605x/ac2492
Abstract
Aseptic loosening of artificial joints is the most common complication after artificial joint replacement. Finding the solution to tackle aseptic loosening of artificial joints is a focus in bone and joint surgery research field. In vitro studies of Sr-doped calcium polyphosphate (SCPP) have found by our team that it could promote osteoblast proliferation and inhibit osteoclast activity, and it has a potential inhibitory effect on aseptic loosening by suppressing the expression of receptor activator of nuclear factor-kappa B ligand and improving the expression of OPG. The present study aims to confirm the conclusion in vitro by the mean of animal experiment. The Ti rod prosthesis coated with SCPP, calcium polyphosphate (CPP), and Ultra-high molecular weight polyethylene (UHMWPE were implanted in the femur (the internal surface of bone tunnel was also coated with SCPP, CPP and UHMWPE respectively). Radiography (x-rays, micro-CT), histochemistry (Hematoxylin-eosin staining (HE), methylene blue-acid fuchsin, Von Kossa histological staining), molecular biology (alkaline phosphatase and TRAP5b factors, Mir21-5p and Mir 26a-5p) were performed to analyzed the effects of SCPP within 20 weeks. The Radiography results showed that osteolysis with various severity occurred in all groups, and SCPP group had the mildest osteolysis. Histochemistry results showed that arthritis was milder in SCPP and CPP groups, while the bone formation in SCPP group was most significant. Its bone reconstruction effect was the best as well. The Molecular biology results showed that the bone reconstruction was out-sync in each group. Compared with other groups, the bone resorption occurred at the latest and the bone resorption time was the shortest in experimental animals of SCPP group. All results indicated that SCPP could promote osteoblast activity and bone reconstruction, improve the integration of bone interface between prosthesis and base bone, reduce osteoclast activity and shorten the osteoclast action time at the implantation site in vivo. Thus, it could postpone or alleviate the occurrence and development of aseptic loosening in vivo. Therefore, SCPP could be a promising material for the construction of artificial joints with the ability to resist aseptic loosening.Keywords
Funding Information
- the Key Research and Development Program of Sichuan Province (2019YFS0121)
This publication has 37 references indexed in Scilit:
- Tumor necrosis factor α suppresses the mesenchymal stem cell osteogenesis promoter miR-21 in estrogen deficiency–induced osteoporosisJournal of Bone and Mineral Research, 2012
- The Normal SynoviumThe Open Rheumatology Journal, 2011
- The Early Fracture Hematoma and Its Potential Role in Fracture HealingTissue Engineering, Part B: Reviews, 2010
- Osteoblasts play key roles in the mechanisms of action of strontium ranelateBritish Journal of Pharmacology, 2009
- Dual effect of strontium ranelate: Stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitroBone, 2008
- Tartrate-resistant acid phosphatase 5b (TRAP 5b) as a marker of osteoclast activity in the early phase after cementless total hip replacementActa Orthopaedica, 2007
- Bone RemodelingAnnals of the New York Academy of Sciences, 2006
- Effect of strontium ions on the growth of ROS17/2.8 cells on porous calcium polyphosphate scaffoldsBiomaterials, 2006
- Lymphocyte function in wound healing and following injuryBritish Journal of Surgery, 1998
- Comparison of bone–implant interface shear strength of solid hydroxyapatite and hydroxyapatite‐coated titanium implantsJournal of Biomedical Materials Research, 1993